Barclays lowered the firm’s price target on Veeva (VEEV) to $305 from $325 and keeps an Overweight rating on the shares. The most incremental data point from the earnings is that Veeva expects to retain 14 of the top 20 pharmas on Vault, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva Systems Reports Strong Q3 Earnings Growth
- Veeva Systems Maintains Strong Buy Rating Amid Robust Financial Performance and Strategic Growth
- Closing Bell Movers: Elastic down 12% despite beat and raise
- Veeva reports Q3 adjusted EPS $2.04, consensus $1.95
- Veeva sees Q4 adjusted EPS $1.92, consensus $1.90